Status note Phase IIb trial in osteosarcoma completed. FDA Rare Pediatric Disease and Fast Track designated. BLA activities in progress.
OST-tADC
Preclinical · ActiveModality: tunable drug conjugate
Aliases OST-tADC-A (Exatecan-silanol-FRa)
Target Folate receptor alpha (FRa)
Partnerships BlinkBio (in-licensed tunable drug conjugate technology)
Indications
Ovarian cancer and other folate receptor alpha-overexpressing tumors(Preclinical)
Status note Tunable drug conjugate platform (ligand, payload, linkers). Lead program OST-tADC-A (Exatecan-silanol-FRa) planned for IND to initiate a Phase 1 trial in ovarian cancer and other folate receptor alpha-overexpressing tumors including endometrial cancer and certain osteosarcomas, pending preclinical and GLP toxicology completion.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.